Exploring the potential prognostic effect of various country-specific health service data on all-cause mortality using data from a large prospective study in schizophrenia

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 9, 2013, Pages 925-932

  Mittoux, Aurélia ^a   Tanghøj, Per ^a   Moore, Nicholas ^b  

^a H LUNDBECK A S   (Denmark)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Health services; Pharmacoepidemiology; Prognostic effect; Region; Schizophrenia; Time to death

Indexed keywords

RISPERIDONE; SERTINDOLE;

ADULT; AGED; ARTICLE; ASIA; CAUSE OF DEATH; CONTROLLED STUDY; DEMOGRAPHY; DRUG SAFETY; DYING; EUROPE; FEMALE; HAZARD RATIO; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH SERVICE; HOSPITAL BED; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHARMACOEPIDEMIOLOGY; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PUBLIC HEALTH; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHIZOPHRENIA; SUICIDE ATTEMPT; WORLD HEALTH ORGANIZATION;

HEALTH SERVICES; PHARMACOEPIDEMIOLOGY; PROGNOSTIC EFFECT; REGION; SCHIZOPHRENIA; TIME TO DEATH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIA; CAUSE OF DEATH; EUROPE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PUBLIC HEALTH; SCHIZOPHRENIA; SOCIOECONOMIC FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84882647070     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3372     Document Type: Article

References (27)

1. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiat 2000; 177: 212-217.
2. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45: 21-28.
3. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Mental disorders and cause-specific mortality. Br J Psychiat 2001; 179: 498-502.
4. Heila H, Haukka J, Suvisaari J, Lonnqvist J. Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol Med 2005; 35: 725-732.
5. Desai MM, Rosenheck RA. Trends in discharge disposition, mortality and service use among long-stay psychiatric patients in the 1990s. Psychiat Serv 2003; 54: 542-548.
6. Junghan UM, Brenner HD. Heavy use of acute in-patient psychiatric services: the challenge to translate an utilisation pattern into service provision. Acta Psychiat Scand Suppl 2006; 429: 24-32.
7. Kent S, Yellowlees P. The relationship between social factors and frequent use of services. Aust N Z J Psychiat 1995; 29: 403-408.
8. Saarento O, Nieminen P, Hakko H, Isohanni M, Vaisanen E. Utilisation of psychiatric in-patient care among new patients in a comprehensive community-care system: a 3-year follow-up study. Acta Psychiat Scand 1997; 95: 132-139.
9. Simpson JC, Tsuang MT. Mortality among patients with schizophrenia. Schizo Bull 1996; 22: 485-499.
10. Brown S. Excess mortality of schizophrenia: a meta-analysis. Brit J of Psy 1997; 171: 502-508.
11. Peuskens J, Tanghøj P, Mittoux A. The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology. Pharmacoepidemiol Drug Saf 2008; 17: 425-433.
12. Thomas SHL, Drici MD, Hall GC, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiat Scand 2010; 122(5): 345-355.
13. Crocq MA, Naber D, Lader MH, et al. Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. European Neuropsy 2010; 20: 829-838.
14. Hert M, Mittoux A, He Y, Peuskens J. A head-to-head comparison of sertindole and risperidone on metabolic parameters. Schizophrenia Res 2010; 123: 276-277.
15. De Hert M, Mittoux A, He Y, Peuskens J. Metabolic parameters in short-and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci 2011; 261: 231-239.
16. Have M, Oldehinkel A, Vollebergh W, et al. Does educational background explain in-equalities in care and service use for mental health problems in the Dutch general population? Acta Psy Scand 2003; 107: 178-187.
17. Vega WA, Koloby B, Aguilar-Gxiola S, et al. Gaps in service utilisation by Mexican Americans with mental health problems. Am J of Psy 1999; 156: 928-934.
18. Barney D. Use of mental health services by American Indian and Alaska Native elders. Am Indian Alsk Native Ment Health Res 1994; 5: 1-14.
19. Barreto RM, Segal SP. Use of mental health services in by Asian Americans. Psychiatr Serv 2005; 56: 746-748.
20. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part2: health outcomes and satisfaction care. Ann Intern Med 2003; 138(4): 288-298.
21. Hesdorffer DC, Tomson T, Benn E, et al. Combined analysis of risk factors for SUDEP. Epilepsia 2011; 52(6): 1150-1159.
22. Ko Y, Malone DC, Skrepnek GH, et al. escribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf 2008; 31(6): 525-536.
23. Lee J, Park S, Choi K, Kwon SM. The association between the supply of primary care physicians and population health outcomes in Korea. Fam Med 2010; 42(9): 628-635.
24. Ran MS, Yu-Hai Chen E, Conwell Y, et al. Mortality in people with schizophrenia in rural China: a 10-year cohort study. Brit J of Psy 2007; 190: 237-242.
25. Davis P, Lay-Yee R, Scott A, Gauld R. Do hospital bed reduction and multiple system reform affect patient mortality?: A trend and multilevel analysis in New Zealand over the period 1988-2001. Med Care 2007; 45(12): 1186-1194.
26. Desai MM, Rosenheck RA. Trends in discharge disposition, mortality, and service use among long-stay psychiatric patients in the 1990s. Psychiatr Serv 2003; 54(4): 542-548.
27. Salokangas RK, Honkonen T, Stengard E, Koivisto AM. Mortality in chronic schizophrenia during decreasing number of psychiatric beds in Finland. Schizophr Res 2002; 54(3): 265-275.